| abstract |
REFERS TO A METHOD TO TREAT A PROLIFERATIVE DISEASE SUCH AS BREAST CANCER, LUNG, PANCREATIC, COLON, LEUKEMIA, MYELOID, MELANOMA IN A PATIENT WHO OPTIONALLY HAS A RISK FACTOR SUCH AS BREAST CANCER, LUNG, PANCREATIC, COLON, LEUKEMIA MYELOID, MELANOMA IN A PATIENT WHO OPTIONALLY HAS A RISK FACTOR OF CARDIAC COMBINATION OR HAS RECEIVED A COMBINATION OF CARDIAC OR HAVE RECEIVED A COMBINATION OF CARDIAC COMPETITION COMPOSITION INCLUDING DOXORUBICIN.HCl, SODIUM SALT OF N- (CARBONYL-METOXYPOLYETHYLENE GLYCOL 2000) -1,2-DIESTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE, SOYAPHOSPHATIDYLCHOLINE, COMPLETELY HYDROGENIC HYDROGENIC COLLIDRODOLINE, COLLYDROIDOLED SOYACIM PHOSPHATIDYLCHOLINE, HYDROGENED COLLYDRODOLINE SODIUM, AMMONIUM SULPHATE, SACROSE IN A RATIO OF 1.0: 1.60: 4.80: 1.60 mg / ml WITH A GROWTH FACTOR RECEPTOR INHIBITOR SUCH AS AN ANTIBODY AGAINST THE EXTRACELLULAR DOMAIN OF A RECEPTOR GROWTH FACTOR OR IS A MONOCLONAL ANTIBODY DIRECTED AGAINST THE EXTRACELLULAR DOMAIN OF AN ERBB2 TYROSINE KINASE RECEPTOR EXPRESSED ON THE SURFACE OF CANCER CELLS SUCH AS TRASTUZUMAB; IT ALSO INCLUDES AN ADDITIONAL ANTINEOPLASTIC SUCH AS URACIL MUSTARD, FROM 400 mg / Kg TO 600mg / Kg OF CYCLOPHOSPHAMIDE, FLUDARABIN, MELFALAN, CHLORAMBUCIL, TEMOZOLOMIDE, 5-FLUOROURACILUS, PHOSPHOSPHENE, CARBONYPHENE, TAMOXYPHENE, NAVELOPHENE, TAMOXYPHENE, FLUDARABIN, NAVEL ANASTRAZOLE, LETRAZOLE, CAPECITABIN |